- Home
- AU vs BIO Comparison
AU vs BIO Comparison
Compare AU & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- BIO
- Stock Information
- Founded
- AU 1944
- BIO 1952
- Country
- AU United States
- BIO United States
- Employees
- AU N/A
- BIO N/A
- Industry
- AU Precious Metals
- BIO Biotechnology: Laboratory Analytical Instruments
- Sector
- AU Basic Materials
- BIO Industrials
- Exchange
- AU Nasdaq
- BIO Nasdaq
- Market Cap
- AU 9.6B
- BIO 8.7B
- IPO Year
- AU 1972
- BIO N/A
- Fundamental
- Price
- AU $26.47
- BIO $327.48
- Analyst Decision
- AU Hold
- BIO Buy
- Analyst Count
- AU 5
- BIO 4
- Target Price
- AU $28.50
- BIO $369.00
- AVG Volume (30 Days)
- AU 1.6M
- BIO 209.2K
- Earning Date
- AU 08-06-2024
- BIO 10-24-2024
- Dividend Yield
- AU 0.77%
- BIO N/A
- EPS Growth
- AU N/A
- BIO N/A
- EPS
- AU 0.27
- BIO N/A
- Revenue
- AU $4,948,000,000.00
- BIO $2,562,604,000.00
- Revenue This Year
- AU $27.08
- BIO N/A
- Revenue Next Year
- AU $4.09
- BIO $4.49
- P/E Ratio
- AU $105.12
- BIO N/A
- Revenue Growth
- AU 9.18
- BIO N/A
- 52 Week Low
- AU $14.91
- BIO $261.59
- 52 Week High
- AU $32.57
- BIO $384.37
- Technical
- Relative Strength Index (RSI)
- AU 36.27
- BIO 50.13
- Support Level
- AU $28.31
- BIO $326.40
- Resistance Level
- AU $29.40
- BIO $337.50
- Average True Range (ATR)
- AU 0.61
- BIO 8.43
- MACD
- AU -0.47
- BIO -0.31
- Stochastic Oscillator
- AU 0.54
- BIO 47.99
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About BIO Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (56% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (44% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (42% of 2023 sales), Europe (31%), Asia (31%), and other (6%). Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.